Interdisciplinary decision making in prostate cancer therapy – 5-years’ time trends at the Interdisciplinary Prostate Cancer Center (IPC) of the Charité Berlin
D. Baumunk(Klinikum Magdeburg), Martin Schostak(Aturo), Carsten Kempkensteffen(Charité - Universitätsmedizin Berlin), Stefan Höcht, Julien Kushner(Humboldt-Universität zu Berlin), Roman Reunkoff(Klinikum Chemnitz), Ursula Steiner(Humboldt-Universität zu Berlin), Kurt Miller(Charité - Universitätsmedizin Berlin), Mark Schrader(Arbeitsgemeinschaft Urologische Onkologie), Lutz Moser(Helios Klinikum Emil von Behring), Alexandra Baumunk(University Hospital Magdeburg), Steffen Weikert(St. Hedwig-Krankenhaus), Thomas Wiegel(University Hospital Ulm)
Cited by 9
Related Papers
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
|The Lancet Oncology|2015|1.4k
The Epidemiology of Renal Cell Carcinoma
|European Urology|2011|1k
Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study
|European Urology|2016|414
Bladder cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2011|249